Text Size

The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension

This study has been completed.
Sponsor:
Collaborators:
Ontario Ministry of Agriculture, Food and Rural Affairs
Ontario Ginseng Growers Association
Information provided by:
Risk Factor Modification Centre
ClinicalTrials.gov Identifier:
NCT00219960
First received: September 14, 2005
Last updated: NA
Last verified: June 2004
History: No changes posted

September 14, 2005
September 14, 2005
April 2001
Not Provided
Mean 24 Hour Ambulatory Blood Pressure
Same as current
No Changes Posted
  • Mean Daytime Ambulatory Blood Pressure
  • Mean Nighttime Ambulatory Blood Pressure
  • Cystatin C
Same as current
Not Provided
Not Provided
 
The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension
The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension

To determine the effect of North American ginseng on blood pressure in individuals with hypertension.

Ginseng lacks proper clinical scrutiny for its effect on blood pressure (BP), in spite of observational evidence linking its intake to hypertension. This should be addressed considering the potential overlap between the prevalence of ginseng use and hypertension.

We undertook a single centre, randomized, controlled, double-blinded, crossover trial to determine the effect of North American ginseng (NAG) on 24-hour BP and renal function. After a 4-week placebo run-in, we randomly assigned participants to NAG or placebo treatment for 12-weeks at a dose of 3g/day. This was followed by an 8-week washout, and a subsequent 12-week period in which the opposite treatment was consumed. At run-in, and at weeks 0 and 12 of each treatment period, participants were fitted with an ambulatory BP monitor to assess 24-hour BP and serum cystatin C was measured.
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Hypertension
Drug: North American Ginseng (Panax Quinquefolius)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
52
October 2003
Not Provided

Inclusion Criteria:

  • aged 18 to 85 years
  • hypertension as defined by the use of antihypertensive drugs or a seated systolic blood pressure greater than or equal to 140 mm Hg or a diastolic BP greater than or equal to 90 mm Hg at each of 3 pre-study visits.

Exclusion Criteria:

  • secondary hypertension
  • diabetes
  • kidney
  • liver disease
  • unstable angina
  • ginseng use for two months prior to or during the study
  • any changes in the type or dose of antihypertensive drugs one month prior to or during the study
Both
18 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00219960
RFMC-0001-77, SR-7093
Not Provided
Not Provided
Risk Factor Modification Centre
  • Ontario Ministry of Agriculture, Food and Rural Affairs
  • Ontario Ginseng Growers Association
Principal Investigator: Vladimir Vuksan, PhD Risk Factor Modification Centre, St. Michael's Hospital
Risk Factor Modification Centre
June 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP